[Caryometry for testing the effectiveness of hormone treatment of carcinoma of the prostate gland (author's transl)].
Control aspiration biopsy should be performed on patients with carcinoma of the prostate gland, because the tumour cells show morphological signs of regression if estrogen therapy is successful: the nuclei of the tumor cells shrink. This can be measured by caryometry. In tumors refractory to estrogen primarily, the nuclei fail to shrink, whereas in tumors refractory to estrogen secondarily, the nuclei reexpand. The cytologic-caryometric findings are therefore an important means of assessing the effectiveness of hormone therapy.
D001706:Biopsy; D002369:Castration; D002467:Cell Nucleus / Q000648:ultrastructure; D004958:Estradiol / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D007620:Karyometry; D008297:Male; D009943:Organophosphorus Compounds / Q000627:therapeutic use; D011379:Prognosis; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000601:surgery / Q000648:ultrastructure*
D009943:Organophosphorus Compounds; D004958:Estradiol; C008958:polyestradiol phosphate
Karyometrie zur Verlaufskontrolle beim hormonbehandelten Prostatakarzinom.